PAP
BNTC icon

Persistent Asset Partners’s Benitec Biopharma BNTC Stock Holding History

Persistent Asset Partners’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$167K Sell
12,493
-5,814
-32% -$69K 0.05% 240
2026
Q1 		$195K Sell
18,307
-2,446
-12% -$28.3K 0.07% 195
2025
Q4 		$280K Buy
+20,753
New +$287K 0.13% 187

Other funds holding BNTC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Persistent Asset Partners's BNTC Position: Q2 2026 in Review

Persistent Asset Partners reduced its Benitec Biopharma (BNTC) stake by 32% in Q2 2026, selling an estimated $69K and leaving 12,493 shares worth $167K. The position accounts for 0.05% of the portfolio, ranked #240.

Persistent Asset Partners first reported a position in BNTC in Q4 2025 and has held it in 3 quarters since. The position peaked at $280K in Q4 2025. 87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • Persistent Asset Partners held 12,493 shares of Benitec Biopharma worth $167K as of Q2 2026.
  • Persistent Asset Partners sold 5,814 Benitec Biopharma shares in Q2 2026, an estimated $69K.
  • Benitec Biopharma made up 0.05% of Persistent Asset Partners's portfolio in Q2 2026, its #240 holding.
  • Persistent Asset Partners first reported a position in Benitec Biopharma in Q4 2025 and has held it in 3 quarters since.
  • Persistent Asset Partners's Benitec Biopharma position peaked at $280K in Q4 2025.
  • 87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.